Green Journals

International Approved Journals

Journal Information

Journal Title	Immunotherapy
Publisher	Taylor and Francis Ltd.
ISSN	1750-743X
E-ISSN	1750-7448
Database	SCOPUS
Domain	Health Sciences, Life Sciences, Social Sciences

Classification History

Year	A+	A	B	C
2026		✓	✓	
2025		✓	✓	
2024		✓	✓	
2023		✓	✓	
2021/2022		✓	✓	
2020		✓	✓	
2019		✓	✓	
2018		✓		

Classification: The table above shows all journal classifications recorded for each classification year in the Green Journals database. A journal may have more than one classification in the same year.

Recent Articles

Tumor-associated neutrophils in gastric cancer: dual roles with promising prognostic and therapeutic potential
2026-11-11 Pages 1-26
Authors: Kamel A. Saleh, Moamin Mohammad Khdir, S. Renuka Jyothi et al.
DOI: 10.1080/1750743x.2026.2759514

Tumor microenvironment modulation for immunotherapy in colorectal cancer: integrating glycosylation into precision immuno-oncology
2026-11-11 Pages 1-16
Authors: Abdulaziz Alfahed, Glowi Alasiri
DOI: 10.1080/1750743x.2026.2759479

Next-generation dendritic cell and exosome vaccines in NSCLC: integrating personalized medicine, nanotechnology, AI, and microfluidics for enhanced immunotherapy
2026-11-10 Pages 1-34
Authors: Mutaz Jamal Al-Khreisat, Alaa Khalaf Bediwi, Sarah Qutayba Badraldin et al.
DOI: 10.1080/1750743x.2026.2758050

Co-existent autoimmune diseases in people with multiple sclerosis and a review on choice of immunotherapy
2026-11-9 Pages 1-10
Authors: Aliakbar Netterwala, Surabhi Garg, Pritam Majumdar et al.
DOI: 10.1080/1750743x.2026.2759490

Cost-effectiveness analysis of tarlatamab as second-line therapy for small-cell lung cancer after platinum-based chemotherapy
2026-11-9 Pages 1-11
Authors: Zhengxiong Li, Jiaming Zhu, Kai Ma
DOI: 10.1080/1750743x.2026.2758055

Bacterial ghosts: next-generation biological platforms for targeted cancer therapy and immunomodulation
2026-11-8 Pages 1-14
Authors: Ghaleb Oriquat, Jasur Rizaev, Abdulqader Faris Abdulqader et al.
DOI: 10.1080/1750743x.2026.2759526

Target engagement without clinical benefit: a systematic review, mechanism-concordant meta-analysis, and research agenda for Parkinson's disease immunotherapy
2026-11-6 Pages 1-20
Authors: Xingli Zhou, Seidu A. Richard, Zhigang Lan et al.
DOI: 10.1080/1750743x.2026.2756119

Nanobodies as next-generation antigen recognition domains for CAR-based cellular immunotherapies in cancer
2026-11-6 Pages 1-15
Authors: Amirhosein Maali, Shaghayegh Fazelian, Mahdieh Jafari et al.
DOI: 10.1080/1750743x.2026.2755254

Fostamatinib in immune thrombocytopenia: real-world experience in European countries
2026-11-5 Pages 1-9
Authors: Francesco Zaja, Maria Eva Mingot-Castellano, Guillaume Moulis
DOI: 10.1080/1750743x.2026.2754679

Macrophage-directed immunotherapy in Inflammatory bowel disease: advances in reprogramming intestinal phagocytes
2026-11-1 Pages 1-29
Authors: Yunting Shao, Shaochen Yu
DOI: 10.1080/1750743x.2026.2758058